FDA Approves Repotrectinib for Patients with NTRK Gene Fusion-Positive Solid Tumors

Friday, 14 June 2024 | Solid Tumors

The FDA has granted accelerated approval to repotrectinib for the treatment of adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. This approval targets patients with locally advanced or metastatic tumors, or those for whom surgical resection would likely result in severe morbidity, and who have either progressed following prior treatment or have no satisfactory alternative therapies.

To continue, please login or sign up first